Ask AI
Current Evidence and Innovative Strategies for mCRC

CE / CME

Metastatic CRC: Personalizing Patient Care Using Current Evidence and Innovative Therapeutic Strategies

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: October 15, 2025

Expiration: April 14, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A patient was recently diagnosed with mCRC, including multiple liver lesions and retroperitoneal lymphadenopathy. Their molecular profile is: pMMR/MSS, BRAF V600E mutation, HER2 negative, KRAS wild type. What would be your recommendation for this patient’s treatment?

2.

Based on current guideline recommendations, which of the following patients with mCRC could be considered for adagrasib or sotorasib + an EGFR inhibitor?

3.

After progression on first-line chemotherapy + bevacizumab, a patient with mCRC starts T-DXd. On his most recent scan, his right lung shows signs of asymptomatic ILD. How would you manage this patient’s grade 1 ILD?